Abstract
Long non-coding RNAs (lncRNAs) have been identified as influential indicators in variety of malignancies. Among which, LncRNA RUNDC3A-AS1 is reported to upregulate in thyroid cancer. However, the expression pattern and the pathological function of lncRNA RUNDC3A-AS1 in thyroid cancer is unclear. In this study, we examined the expression levels of lncRNA RUNDC3A-AS1 in the thyroid cancer tissues and cell lines via RT-qPCR analysis. The effects of RUNDC3A-AS1 on thyroid cancer cell metastasis were detected by transwell chamber assay, scratch assay in vitro and lung metastasis model in vivo. The results indicated that RUNDC3A-AS1 was highly expressed in the thyroid cancer tissues and cell lines. Functionally, knockdown of RUNDC3A-AS1 could repress the migration and invasion of thyroid cancer cells in vitro, and inhibit thyroid cancer metastasis to lung in vivo. Mechanistically, RUNDC3A-AS1 served as an inhibitor of miR-182-5p in tumor tissues and cell lines. RUNDC3A-AS1 inhibited the expression of miR-182-5p to increase the expression level of ADAM9, thus further aggravating the malignancy of thyroid cancer. Therefore, the RUNDC3A-AS1/miR-182-5p/ADAM9 axis may be a potential therapeutic target for the treatment of thyroid cancer metastasis.
Highlights
Thyroid carcinoma (TC) is the most common endocrine malignancy and its incidence is annually increasing in the world (Yapa et al, 2017; Baloch and LiVolsi, 2018)
All these results revealed that RUNDC3A-AS1 was positively correlated with thyroid cancer progression
The results suggested that the expression levels of RUNDC3AAS1 in thyroid cancer tissues and cell lines were positively correlated with ADAM9 expression (Figure 5G), while the expression levels of miR-182-5p were negatively correlated with ADAM9 expression (Figure 5H)
Summary
Thyroid carcinoma (TC) is the most common endocrine malignancy and its incidence is annually increasing in the world (Yapa et al, 2017; Baloch and LiVolsi, 2018). PTC accounts for 75–80% and is the predominant thyroid cancer (La Vecchia et al, 2015; Mao and Xing, 2016). The RUNDC3A-AS1 Accelerates TC Metastasis by miR-182-5p/ADAM9 molecular mechanism of thyroid carcinoma pathogenesis is unclear (Zaballos and Santisteban, 2017). It is urgent to better understand the molecular mechanism of initiation and progression of thyroid cancer, which may contribute to the diagnosis and treatment of this cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
